Panacea Announces Launch of New Product COVID CBDA(TM)

"Orally bioavailable and with a long history of safe human use, these cannabinoids, isolated or in hemp extracts, have the potential to prevent as well as treat infection by SARS-CoV-2" the researchers stated in the published study.

GOLDEN, CO / ACCESSWIRE / January 18, 2022 / Panacea Life Sciences Holdings, Inc. (OTCQB:PLSH) ("Panacea" or the "Company"), a Colorado, USA-based cannabinoid research-focused company providing natural, non-habit-forming health and wellness products as an alternative to Big Pharma product offerings, is pleased to announce the launching of its immunity-boosting product, COVID CBDA™.

Foto: Accesswire

A recent laboratory study executed by Oregon State University (OSU) - which did not involve any human trials - found that the cannabinoids cannabidiolic acid (CBDA) and cannabigerolic acid (CBGA), which are present in industrial hemp (scientifically known as Cannabis sativa L), have shown the ability to bind to COVID-19 proteins and inhibit the virus from entering or infecting human cells. Lead researcher Richard van Breemen and his colleagues found that when the pair of cannabinoids bind to the SARS-CoV-2 spike protein, they can block the protein from binding to human cells, thus inhibiting the ability of COVID-19 to infect humans. The spike protein is the target for antibody therapies, and this inhibition method is used to develop vaccines.

In OSU's newsroom article, van Breemen explained, "These cannabinoid acids are abundant in hemp and in many hemp extracts. They are not controlled substances like THC, the psychoactive ingredient in marijuana, and have a good safety profile in humans. Our research showed the hemp compounds were equally effective against variants of SARS-CoV-2, including the Delta variant, which was first detected in the United Kingdom, and the Omnicron variant, first detected in South Africa."

According to Panacea's Chief Science Officer, James Baumgartner, Ph.D., "Panacea's new COVID CBDA™ product contains a significant amount of these COVID-19 blocking cannabinoids, along with additional immunity-building ingredients to give our customers a fighting chance against COVID-19. The new information discovered in this study is encouraging and paramount for Panacea. As a leading cannabinoid research company, our goal to conduct further research and studies that can impact the medical community is a top priority."